Reorganization of public procurement of biosimilars and its economic effect on the monoclonal antibody market in Russia

Background. The increasing number of registered biosimilarsof monoclonal antibodies (mAbs) is altering the structure of the pharmaceutical market by amplifying the share of domestic manufacturers. Therefore, investigating their economic effect appears highly relevant.

Objective: To examine the impact of biosimilars on the market for public procurement of medicinal products based mAbs during the period 2022–2023.

Material and methods. A list of registered drugs based on mAbs was compiled from the State Register of Medicines and the Unified Information System for Procurement databases. The study involved statistical and marketing methods, including normalization of drug costs to weighted average prices (rub/mg), ABC analysis to identify key positions based on expenditure, and competitive analysis to categorize drugs as either original or biosimilars.

Results. The analysis of weighted average prices for original drugs and biosimilars, as well as their procurement volumes, demonstrated a significant economic effect on the health care system. The greatest savings were achieved through the procurement of bevacizumab and pembrolizumab biosimilars, resulting in savings of 15.1 and 3.8 billion rubles, respectively. In the group of rituximab drugs, procurement of biosimilars led to savings of approximately 2 billion rubles.

Conclusion. The introduction of biosimilars into the public procurement market has significantly optimized costs, thereby increasing patient access to life-saving medicines. The results emphasize the necessity for further development of biosimilars market to enhance the efficiency of public procurement and improve drug accessibility. However, a comprehensive understanding of their economic advantages require clinical studies that confirm the efficacy and safety of biosimilars in real-world clinical practice.

1. Kirsanova O.V., Omelyanovsky V.V. Options to optimize the access to biosimilars: analysis and solutions. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2018; 11 (1): 50–5 (in Russ.). https://doi.org/10.17749/2070-4909.2018.11.1.050-055.

2. Tryakin A.A., Rudakova A.V., Vogt S.N., et al. Pharmacoeconomical aspects of biosimilars. Journal of Modern Oncology. 2017; 19 (1): 42–7 (in Russ.).

3. World Health Organization. Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs), Annex 2, TRS No 1004. Available at: https://www.who.int/publications/m/item/mAbs-trs-no-1004-a2 (accessed 15.09.2024).

4. Valieva O.V. Biotechnology market development: global trends and the place of Russia. World of Economics and Management. 2021; 21 (4): 82–102 (in Russ.). https://doi.org/10.25205/2542-0429-2021-21-4-82-102.

5. Dutta B., Huys I., Vulto A.G., Simoens S. Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price! BioDrugs. 2020; 34: 159–70. https://doi.org/10.1007/s40259-019-00395-w.

6. State Register of Medicines. Available at: https://grls.minzdrav.gov.ru/default.aspx (in Russ.) (accessed 15.09.2024).

7. Federal State Statistics Service. Available at: https://rosstat.gov.ru/ (in Russ.) (accessed 15.09.2024).

8. Unified Information System for Procurement. Available at: https://zakupki.gov.ru/epz/main/public/home.html (in Russ.) (accessed 15.09.2024).

9. The Ministry of Industry and Trade of Russia. Pharmaceutical and medical industry. Available at: https://minpromtorg.gov.ru/activities/industries/otrasli/farma (in Russ.) (accessed 15.09.2024).

10. Milko V.O. Forecasting the development of the pharmaceutical market in Russia. In: Bespartochnyy B.D. (Ed.) Topical issues of sustainable development of modern society and economy: collection of scientific articles of the 2nd All-Russian Scientific and Practical Conference. Vol. 2. Kursk: Universitetskaya kniga: 97–100 (in Russ.).

11. Uvarov D.A. The economic effect of biosimilars government procurement on the monoclonal antibodies market in Russia. Public Administration. E-journal (Russia). 2021; 84: 129–46 (in Russ.). https://doi.org/10.24412/2070-1381-2021-84-129-146.

12. Ushkalova E.A., Zyryanov S.K., Gopienko I.A. Economic challenges of oncological diseases’ pharmacotherapy. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020; 13 (1): 64–70 (in Russ.). https://doi.org/10.17749/2070-4909.2020.13.1.64-70.

13. DSM Group. Pharmaceutical market of Russia 2023. Available at: https://dsm.ru/docs/analytics/Annual_report_2023_RUS_.pdf (in Russ.) (accessed 15.09.2024).

14. Rayskaya M.V. Analysis of the innovative development of the biotechnological sector of the Russian economy. In: Sirotkin А.S. (Ed.) Food technologies and biotechnologies. Proceedings of the XVIII All-Russian Conference of Young Scientists, Postgraduates and Students with International Participation. Kazan: Kazan National Research Technological University; 2023: 837–41 (in Russ.).

15. Prospects for the development of the pharmaceutical industry in Russia. Available at: https://yakovpartners.ru/publications/russian-pharma-2030/ (in Russ.) (accessed 15.09.2024).

16. Samoshchenkova I.F., Fokina O.A. Development strategy of the pharmaceutical industry in Russia: results, goals, objectives. In: New challenges – new research. Collection of articles of the IV International Scientific and Practical Conference. Petrozavodsk; 2023: 96–100 (in Russ.).

17. Khalimova A.A., Orlov A.S., Taube A.A. Analysis of biopharmaceutical manufacturing localisation in Russia considering the country of origin of active pharmaceutical ingredients. Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation. 2024; 14 (1): 53–61 (in Russ.). https://doi.org/10.30895/1991-2919-2024-14-1-53-61.

18. Denisova A.I., Sozaeva D.A., Gonchar K.V., Aleksandrov G.A. Improving the methodology for assessing the economic efficiency of public e-procurement of medicines. Financial Journal. 2023; 15 (4): 63–81 (in Russ.). https://doi.org/10.31107/2075-1990-2023-4-63-81.